Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
Phase 4
Completed
- Conditions
- Autism Spectrum DisorderAttention-deficit/Hyperactivity Disorder
- Interventions
- Registration Number
- NCT02096952
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
The purpose of this study is to determine whether methylphenidate hydrochloride extended release liquid formulation is safe and effective in the treatment of attention-deficit/hyperactivity disorder (ADHD) in high-functioning adults with autism spectrum disorders (ASD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Methylphenidate extended-release liquid Methylphenidate extended-release liquid formulation Methylphenidate extended-release liquid formulation
- Primary Outcome Measures
Name Time Method Change in Adult ADHD Investigator Symptom Report Scale (AISRS) Score Baseline to 6 weeks The Adult ADHD Investigator Symptom Report Scale (AISRS) assesses each of the 18 individual symptoms of ADHD in DSM-IV on a Likert scale from 0 (not present) to 3 (severe), with a total possible score of 54.
The change in AISRS score from baseline to endpoint (6 weeks) was calculated as the later time point score minus the earlier time point score.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States